Head and Neck Cancer Market

Head and Neck Cancer Market (Drug Class: EFGR Inhibitors, Mitotic Inhibitors, Anti-PD-1 Monoclonal Antibodies, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Head and Neck Cancer Market Outlook 2031

  • The global industry was valued at US$ 1.6 Bn in 2022
  • It is estimated to grow at a CAGR of 6.8% from 2023 to 2031 and reach US$ 2.9 Bn by the end of 2031

Analyst Viewpoint

Unhealthy lifestyle habits and various genetic predispositions are driving the head and neck cancer market size. Rapid breakthroughs in radiation treatment and enhanced post-treatment rehabilitation are also boosting the demand for head and neck cancer treatment. High levels of air and environmental pollution, alongside genetic abnormalities resulting from the presence of toxic chemicals in the food chain have been associated with various health risks, including potential links to certain types of cancer.

Rise in investment in healthcare infrastructure in developing economies and growth in popularity of medical tourism are propelling the head and neck cancer market trajectory. Manufacturers are investing in the R&D of affordable treatment to expand their customer base.

Image Head And Neck Cancer Market

Head and Neck Cancer Market Introduction

Cancer develops when healthy cells mutate and expand uncontrollably, generating a mass known as a tumor. A tumor might be malignant or benign. A malignant tumor can multiply and spread to other sections of the body. A benign tumor can develop but does not spread. The term "head and neck cancer" refers to a variety of types of neck cancer that grow in or around the throat, larynx, nose, sinuses, and mouth.

The tumor can spread (metastasize) from the initial location to other body parts. Cancer is usually referred to by the site where it first appeared. Lung cancer that spreads to the liver, for example, is still referred to as lung cancer. Distinct forms of cancer have significantly different behaviors. They might develop at different speeds and react to various therapies. Thus, patients with cancer require treatment tailored to their specific form of disease.

Squamous cell carcinomas account for the majority of head and neck malignancies. This cancer starts in flat squamous cells. These cells form the thin layer of tissue that covers the structures in the head and neck. These structures contain mucosa beneath this layer, which is termed epithelium - a moist tissue present in the head and neck. Carcinoma in situ refers to a malignancy only located in the layer of squamous cells (epithelium), mostly presenting cancer in the neck area. If the disease has spread past this cell layer and into deeper tissue, it is called invasive squamous cell carcinoma. If physicians cannot pinpoint the disease's origin, it is referred to as cancer of unknown primary.

Unhealthy Lifestyle Habits and Various Genetic Predispositions Augmenting Head and Neck Cancer Market Revenue

Tobacco (smoked or chewable), alcohol, areca nut, and malnutrition are all prevalent etiological variables that are also critical downstream socioeconomic determinants. Heavy smokers and drinkers are 35 times more likely to get head and neck cancer. Vitamin A, C, E, iron, selenium, and zinc deficits are also factors. Increased salt-preserved food consumption, grilled barbecued meat, and frozen and processed foods are all well-known etiological variables. Other contributing variables include exposure to air pollution, excessive sunshine, and other carcinogens. Clinical trials for HPV-positive head and neck cancer, as well as other specific viruses, such as HPV, EBV, Herpes, and HIV, have cemented in literature their role in causing cancer. Hence, unhealthy lifestyle habits are driving the head and neck cancer market.

Genetic abnormalities have been linked with the disease, though environmental variables play an essential role. People with a first-degree family history of head and neck cancer have a risk of 3.5-3.8, whereas persons with multiple primaries in the family have an eight-fold risk. Patients with a poor ability to metabolize toxins and a weakened immune system are around 500-700 times more likely to acquire malignant carcinomas. Rise in incidences of immune disorders and increase in influx of carcinogens into the body from the environment are projected to significantly influence the head and neck cancer market development in the near future.

Rapid Breakthroughs in Radiation Treatment and Enhanced Post-Treatment Rehabilitation

Significant advances have been made in the Radiation Treatment (RT) of head and neck cancers over recent years. The introduction of multimodality imaging for target volume and organs at risk delineation and intensity-modulated RT has improved the efficacy of RT. The use of altered fractionation regimens and concurrent administration of chemotherapy for targeted areas have further enhanced the post-RT outcomes for patients. One such example is the massive strides made in speech therapy post-treatment for throat cancer. Overall, such advancements have resulted in improved locoregional control and overall survival probability, a reduction in the long-term harmful effects of RT, and a subsequent increase in quality of life. This, in turn, is fueling the head and neck cancer market value.

Further advancements in the treatment of head and neck cancer have resulted from improved integration of molecular imaging to detect tumor sub-volumes. These tumor groups often require more radiation doses and therapy adaptation to monitor changes in patient anatomy throughout treatment. In other cases, proton treatment produces even more precise dosage distribution, enhancing patient outcomes. Manufacturers in the head and neck cancer market are looking at further progress in this field by focusing on target volume and organ-at-risk delineation, molecular imaging for tumor delineation, dose painting for dose escalation, dose adaptability throughout treatment, and the possible benefit of proton therapy.

Regional Outlook

According to the latest head and neck cancer market trends, North America held largest share in 2022. Increase in prevalence of head and neck cancer, rise in healthcare expenditure, and expansion in pharmaceutical sector are fueling the market dynamics of the region. Presence of a robust product pipeline is also driving the global market statistics.

Rise in demand for effective medications for the treatment of head and neck cancer is boosting the market expansion in Asia Pacific. China and India are major markets for head and neck cancer treatment. Growth in pharmaceutical sector is also influencing the head and neck cancer market share in the region.

The industry in Latin America and Middle East & Africa is projected to grow at a steady pace during the forecast period. Surge in healthcare investment and rise in number of pharmaceutical firms operating locally are boosting the head and neck cancer market landscape in these regions.

Analysis of Key Players

Mergers & acquisitions, new product development, and strategic collaborations with government authorities are major strategies adopted by key players. Manufacturers are introducing innovative drugs and therapy modalities with a focus on improved quality of life for patients. Regulatory support has also enabled businesses to develop a large pipeline of drugs, greatly enhancing the prospects of finding better treatment than the modalities currently available in this landscape.

Major players operating in the global head and neck cancer industry include Sanofi, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, AstraZeneca, Merck KgaA, Bayer AG, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals.

Each of these players has been profiled in the head and neck cancer market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments in Head and Neck Cancer Market

  • In April 2023, Eli Lilly presented the first clinical data on its KRAS G12 inhibitor at the American Association for Cancer Research (AACR) meeting in Orlando. KRAS G12 is a specific genetic mutation in the KRAS oncogene. The KRAS gene produces a protein called K-Ras, which helps to regulate cell growth and division. A mutation in the KRAS gene can lead to the production of a faulty K-Ras protein that is always active, causing cells to grow and divide uncontrollably, resulting in cancer.
  • In August 2022, Eli Lilly and Company announced a clinical trial collaboration and supply agreement (CTCSA) with Erasca, Inc. to evaluate the anti-EGFR antibody cetuximab (Erbitux), supporting the ongoing phase 1/1b FLAGSHP-1 trial (NCT04670679) examining ERAS-601, an oral SHP2 inhibitor in combinations. This includes assessment for the treatment of triple wild-type (KRAS/NRAS/BRAF wild-type) metastatic colorectal cancer (CRC) and human papillomavirus (HPV)-negative advanced head and neck squamous cell carcinoma (HNSCC).

Head and Neck Cancer Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 1.6 Bn
Market Forecast Value in 2031 US$ 2.9 Bn
Growth Rate (CAGR) 6.8%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022 Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • EGFR Inhibitors
    • Mitotic Inhibitors
    • Anti-PD-1 Monoclonal Antibodies
    • Others
  • Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC
  • South Africa
Companies Profiled
  • Sanofi
  • Pfizer
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • AstraZeneca
  • Merck KgaA
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Galera
  • Fresenius Kabi
  • Teva Pharmaceuticals
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the head and neck cancer market in 2022?

It was valued at US$ 1.6 Bn in 2022

How is the head and neck cancer business expected to grow by 2031?

It is likely to grow at a CAGR of 6.8% from 2023 to 2031

What are the key factors driving demand in the head and neck cancer industry?

Unhealthy lifestyle habits and various genetic predispositions along with rapid breakthroughs in radiation treatment and enhanced post-treatment rehabilitation

Which head and neck cancer distribution channel segment held the largest share in 2022?

The hospital pharmacies segment held the largest share in 2022

Which was the major region in the global head and neck cancer landscape in 2022?

North America was the leading region in 2022

Who are the major head and neck cancer vendors?

Sanofi, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, AstraZeneca, Merck KgaA, Bayer AG, Bristol-Myers Squibb Company, Galera, Fresenius Kabi, and Teva Pharmaceuticals

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Head and Neck Cancer Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. EGFR Inhibitors

            6.3.2. Mitotic Inhibitors

            6.3.3. Anti-PD-1 Monoclonal Antibodies

            6.3.4. Others

        6.4. Market Attractiveness, by Drug Class

    7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Distribution Channel, 2017–2031

            7.3.1. Hospitals Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. E-commerce

        7.4. Market Attractiveness, by Distribution Channel

    8. Global Head and Neck Cancer Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Head and Neck Cancer Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Drug Class, 2017–2031

            9.2.1. EGFR Inhibitors

            9.2.2. Mitotic Inhibitors

            9.2.3. Anti-PD-1 Monoclonal Antibodies

            9.2.4. Others

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Hospitals Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. E-commerce

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Drug Class

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Head and Neck Cancer Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Class, 2017–2031

            10.2.1. EGFR Inhibitors

            10.2.2. Mitotic Inhibitors

            10.2.3. Anti-PD-1 Monoclonal Antibodies

            10.2.4. Others

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospitals Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. E-commerce

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Drug Class

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017–2031

            11.2.1. EGFR Inhibitors

            11.2.2. Mitotic Inhibitors

            11.2.3. Anti-PD-1 Monoclonal Antibodies

            11.2.4. Others

        11.3. Market Value Forecast, by Distribution Channel, 2017–2031

            11.3.1. Hospitals Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. E-commerce

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Drug Class

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Head and Neck Cancer Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017–2031

            12.2.1. EGFR Inhibitors

            12.2.2. Mitotic Inhibitors

            12.2.3. Anti-PD-1 Monoclonal Antibodies

            12.2.4. Others

        12.3. Market Value Forecast, by Distribution Channel, 2017–2031

            12.3.1. Hospitals Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. E-commerce

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Drug Class

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017–2031

            13.2.1. EGFR Inhibitors

            13.2.2. Mitotic Inhibitors

            13.2.3. Anti-PD-1 Monoclonal Antibodies

            13.2.4. Others

        13.3. Market Value Forecast, by Distribution Channel, 2017–2031

            13.3.1. Hospitals Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. E-commerce

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Drug Class

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Sanofi

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Pfizer

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. Eli Lilly and Company

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. F. Hoffman-La Roche

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. AstraZeneca

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Merck KgaA

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. Bayer AG

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Bristol-Myers Squibb Company

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. Galera

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. Fresenius Kabi

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

            14.3.11. Teva Pharmaceuticals

                14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.11.2. Product Portfolio

                14.3.11.3. Financial Overview

                14.3.11.4. SWOT Analysis

                14.3.11.5. Strategic Overview

    List of Tables

    Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

    List of Figures

    Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

    Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022

    Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022

    Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031

    Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023–2031

    Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031

    Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023–2031

    Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

    Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

    Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031

    Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved